This application details the collaborative, leadership role of the Gynecologic Oncology Group (GOG) Statistical and Data Center (SDC) in determining the GOG research agenda and accomplishing its mission of promoting excellence in the quality and integrity of clinical and basic scientific research in the field of Gynecologic malignancies. The SDC is comprised of four Divisions (Biostatistics and Science, Information Technology, Data Management, and Administration) and features unparalleled experience in clinical trials investigating gynecologic malignancies. Its members participate in every aspect of Group activities and are inherently involved in GOG Leadership. Specific responsibilities are governed by comprehensive SOPs and embrace all aspects of Group research, including concept development, study design, protocol conduct, data acquisition and quality control, analysis, and publication of results. This grant period has been highlighted by exciting, innovative advances. The SDC has entered into collaboration with the University at Buffalo, Roswell Park Cancer Institute, and the New York State Center of Excellence. This has provided an academic setting for the SDC, and greatly enhanced its scientific expertise with the infusion of faculty with diverse talents. Technologic advances have revolutionized GOG data management with the development and refinement of electronic data submission and specimen tracking. Management strategies have enhanced productivity and efficiency.
The role of the SDC is highly relevant to research in gynecologic oncology. Its members have the responsibility to ensure that the design of the research is feasible, that the data are of high quality and analyzed appropriately, and ultimately, that the results are interpreted properly and disseminated in a timely fashion. The ability to professionally attain these objectives is essential to high quality research.
|Burger, Robert A; Brady, Mark F; Bookman, Michael A et al. (2014) Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 32:1210-7|
|Tewari, Krishnansu S; Sill, Michael W; Long 3rd, Harry J et al. (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734-43|
|Zaino, Richard J; Brady, William E; Todd, William et al. (2014) Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol 33:543-53|
|Duska, Linda R; Blessing, John A; Rotmensch, Jacob et al. (2014) A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 135:44-8|
|Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256|
|Miller, David Scott; Blessing, John A; Ramondetta, Lois M et al. (2014) Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group. J Clin Oncol 32:2744-9|
|Sherman, Mark E; Piedmonte, Marion; Mai, Phuong L et al. (2014) Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol 32:3275-83|
|Powell, Matthew A; Sill, Michael W; Goodfellow, Paul J et al. (2014) A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 135:38-43|
|Brown, Jubilee; Brady, William E; Schink, Julian et al. (2014) Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer 120:344-51|
|Fader, Amanda Nickles; Java, James; Krivak, Thomas C et al. (2014) The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study. Gynecol Oncol 132:560-5|
Showing the most recent 10 out of 373 publications